Statement from LuMind Research Down Syndrome Foundation on the Roche Clinical Trials

Categories: Blog, Clinical Trials, Ds Research, News
From LuMind RDS Board Chairman, Ryan Hartman We thank you for turning to LuMind Research Down Syndrome with your questions and comments about the news of the Roche CLEMATIS Phase 2 clinical trial for RG1662/Basmisanil. As the largest source of private funding for Down syndrome cognition research, we are in contact with many people from our …

Read More

Response to the Roche Clinical Trial for CLEMATIS

Categories: Blog, Ds Research, News
A response from LuMind Research Down Syndrome President and CEO Carolyn Cronin regarding the end of the Roche Clinical Trial for CLEMATIS. Hello friends, Like you we were disappointed to learn about the end of Roche Clinical Trial for CLEMATIS, the Phase II study investigating the efficacy and safety of basmisanil (RG1662) in adults and …

Read More

Ground-breaking New Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome

Categories: Blog, Clinical Trials, Ds Research, News
By Dr. Michael Harpold, LuMind RDS Chief Scientific Officer AC Immune announced the publication of a ground-breaking scientific study on an anti-A-beta vaccine potentially signaling a way to treat cognitive deficits in people with Down syndrome (Ds). The study, entitled An anti-Abeta-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome, was …

Read More

Q&A With Dr. William Mobley

Categories: Blog, Ds Research, News, Why Support Research?

Did you attend our webinar in January and ask a question that wasn’t answered? Dr. William Mobley has the answers! Dr. Mobley from the University of California, San Diego’s Down Syndrome Center for Research and Treatment and Dr. Jamie Edgin from the University of Arizona’s Down Syndrome Research Group spoke at our webinar on January 29, …

Read More

Clinical Trials UPDATE: Roche Initiates RG1662 Phase II Clinical Trials for Individuals with Down syndrome

Categories: Blog, Clinical Trials, Ds Research

LuMind Foundation-supported research has led to clinical trials currently in progress to address developmental cognitive deficits and those impairments associated with Alzheimer’s disease. Roche, a leader in innovative research-focused healthcare and the world’s largest biotech company, has initiated a new multi-national Phase II clinical trial to evaluate the efficacy and safety of RG1662 in adolescents and adults, …

Read More